finding answers to treatment resistance will of necessity require investigation of clinical tumours. Adeniji AO, Chen M, Penning TM (2013) AKR1C3 as a target in castrate resistant prostate cancer.

We've been delighted to see the ICR-discovered NXP800 drug make great progress in clinical studies for ovarian cancer, so it is very exciting to see that it could potentially also benefit prostate ...

Ward Carson didn’t think twice when asked by his doctor to participate in a clinical trial for a treatment for prostate cancer. The 82-year-old retired chartered accountant was diagnosed in 2003 with ...